Ticagrelor Continue vs De Escalate Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Review bleeding and ischemic concerns after PCI. This decision aid does not replace individualized cardiology assessment.

ACS · Post-PCI

Enter 0 for the day of PCI. The first 30 days after ACS are a particularly important period for ischemic risk.

Prior major bleeding after PCI

A clinically important bleeding event since the procedure.

Clinician-identified high bleeding risk

For example, formal assessment using ARC-HBR or PRECISE-DAPT. Do not infer formal HBR from the other fields alone.

Recurrent ischemic event or concern for stent thrombosis

Includes a new event or a clinical concern that requires assessment.

Hemoglobin <11 g/dL or anemia requiring treatment

A bleeding-risk feature; not a stand-alone validated HBR score.

Age 75 years or older

Age contributes to bleeding risk but should be interpreted in the full clinical context.

Renal dysfunction (eGFR <60 mL/min/1.73 m²)

Renal function can affect both bleeding and ischemic risk.

Reset form

Clinical context

After acute coronary syndrome (ACS), aspirin plus an oral P2Y12 inhibitor is the default dual antiplatelet therapy (DAPT) strategy for at least 12 months in patients who are not at high bleeding risk. Ticagrelor or prasugrel is generally preferred to clopidogrel after ACS PCI when suitable.

Alternative strategies can reduce bleeding in selected patients. The 2025 ACC/AHA ACS guideline states that de-escalation from ticagrelor or prasugrel to clopidogrel after 1 month may be reasonable in ACS patients undergoing PCI; in patients who have tolerated ticagrelor-based DAPT, transition to ticagrelor monotherapy at least 1 month after PCI is also a recommended bleeding-reduction strategy. These approaches are not interchangeable and require patient-specific review.

How to interpret this tool

  • Do not use a simple count of the selected features as a validated bleeding-risk score.
  • Recurrent ischemia or suspected stent thrombosis warrants prompt clinical evaluation rather than an automatic medication recommendation.
  • De-escalation in the first 30 days after ACS is generally not recommended as a routine strategy.
  • Consider formal ARC-HBR/PRECISE-DAPT assessment and the patient's ischemic risk, bleeding history, drug tolerance, concomitant anticoagulation, and preferences.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary SyndromesCirculation / JACC. 2025. Recommendations include default 12-month DAPT, ticagrelor monotherapy after at least 1 month in selected patients, and possible DAPT de-escalation to clopidogrel after 1 month.Official guideline DOI: 10.1161/CIR.0000000000001309
2023 ESC Guidelines for the management of acute coronary syndromesEuropean Heart Journal. 2023;44:3720–3826. De-escalation may be considered in selected patients to reduce bleeding; routine de-escalation in the first 30 days is not recommended.Official guideline DOI: 10.1093/eurheartj/ehad191
Kim CJ, et al. TALOS-AMILancet. 2021;398:1305–1316. Unguided de-escalation from ticagrelor to clopidogrel in stabilized patients with acute myocardial infarction after an event-free first month.DOI: 10.1016/S0140-6736(21)01445-8 · PMID: 34627490
Urban P, et al. Defining high bleeding risk in patients undergoing PCI: ARC-HBR consensusEuropean Heart Journal. 2019;40:2632–2653. Consensus definition of high bleeding risk in patients undergoing PCI.DOI: 10.1093/eurheartj/ehz372
Clinical disclaimer: This tool is for clinician decision support and education. It is not a validated risk score and must not be used as the sole basis for changing antiplatelet therapy. Assess active bleeding and suspected acute ischemia urgently. Confirm the current guideline, local protocol, contraindications, medication history, and patient-specific risk before changing treatment.